CCI
AKBA icon

Columbus Circle Investors’s Akebia Therapeutics AKBA Stock Holding History

Columbus Circle Investors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-64,953
Closed -$627K – 278
2015
Q3 		$627K Buy
+64,953
New +$596K 0.01% 261

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Columbus Circle Investors's AKBA Position: Q4 2015 in Review

Columbus Circle Investors sold out of Akebia Therapeutics (AKBA) in Q4 2015, closing a stake of 64,953 shares — an estimated $627K sold.

Columbus Circle Investors first reported a position in AKBA in Q3 2015 and held it in 1 quarter. The position peaked at $627K in Q3 2015. 90 funds tracked by Wall St. Rank hold AKBA as of Q4 2015.

  • Columbus Circle Investors reported no remaining Akebia Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Columbus Circle Investors sold 64,953 Akebia Therapeutics shares in Q4 2015, an estimated $627K.
  • Columbus Circle Investors first reported a position in Akebia Therapeutics in Q3 2015 and held it in 1 quarter.
  • Columbus Circle Investors's Akebia Therapeutics position peaked at $627K in Q3 2015.
  • 90 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2015.

Based on Columbus Circle Investors's 13F filing for Q4 2015, filed 5 Feb 2016.